Fibroblast growth factor 4 gene therapy for chronic ischemic heart disease.
Therapeutic myocardial angiogenesis and arteriogenesis represent a novel treatment strategy for patients with angina refractory to traditional medical and surgical therapies. The fibroblast growth factors are a family of proteins that are known mediators of angio-/arteriogenesis. Based on promising preclinical animal data, a series of four randomized placebo-controlled clinical trials have been conducted to determine the safety and efficacy of local delivery of fibroblast growth factor 4 with the use of adenovirus-vector-mediated gene transfer to induce myocardial angio-/arteriogenesis in patients with stable angina. This review describes the scientific rationale underlying these clinical trials, provides an overview of their results, and discusses the implications for future studies.
Kapur
Navin K
NK
Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.
Rade
Jeffrey J
JJ
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003097:Collateral Circulation; D003326:Coronary Circulation; D051519:Fibroblast Growth Factor 4 / Q000235:genetics / Q000378:metabolism*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D017202:Myocardial Ischemia / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D018919:Neovascularization, Physiologic; D018579:Patient Selection; D013997:Time Factors; D016896:Treatment Outcome
D051519:Fibroblast Growth Factor 4